OPG/RANKL system plays a key role in the pathogenesis of systemic and local bone loss in RA being associated to disease progression [38–41] and is affected by several factors other than GC treatment, including inflammation status and activity disease [42]. The gene discussed is TNFRSF11B; the disease is rheumatoid arthritis.